Summary of whether sotoraxibu (AMG 510) is available in China and how to purchase it

Sotorasib (trade name: Lumakras, code: AMG 510) is an oral targeted drug targeting the KRAS G12C mutation. It is one of the few drugs that can accurately inhibit the KRAS mutation. This type of mutation is common in malignant tumors such as non-small cell lung cancer, so sotoraxib has attracted much attention since its development stage. However, the drug has not yet been approved for marketing in mainland China, and domestic patients cannot purchase the drug directly through regular hospitals or pharmacies. For patients with urgent medication needs, they can only consider purchasing drugs overseas.

In overseas markets, the original drug of sotorasibu has been launched and has been approved by the FDA and EMA for the treatment of locally advanced or metastatic non-small cell lung cancer with KRAS G12C mutations. Its original drugs mainly include the European version and the Hong Kong version. Both are produced through formal channels, but the price is very expensive, often as high as tens of thousands or even tens of thousands of yuan per box. This high cost puts great financial pressure on patients who need to take it for a long time. Therefore, many patients will take the initiative to learn about generic drugs in order to find more cost-effective alternatives.

Currently, some countries have begun to produce generic versions of sotoraxib, with Laos’ generic version being the most typical. Two companies, Laos Lucius (Lucius) and Daxiong (Beacon), have launched generic versions of sotoraxib and have recently seen significant price reductions. Taking the specifications of 120mg*56 tablets as an example, the current price is only more than 1,000 yuan. Compared with the original drug, the cost is significantly lower. This undoubtedly provides a new option for many patients with limited financial conditions but urgent need for targeted therapy, and also gives more people the opportunity to adhere to long-term medication.

It is worth noting that although the active ingredients of original drugs and generic drugs are basically the same, patients still need to carefully confirm the formality of the source of the drugs when choosing purchase channels to avoid purchasing substandard or counterfeit drugs. If possible, it is best to take medication under the guidance of a professional doctor, while paying attention to possible side effects and efficacy monitoring of the medication. Generally speaking, although sotorasibu has not yet been launched in China, obtaining original drugs or generic drugs through overseas formal channels is still the main choice for patients at present.

Reference link:https://www.drugs.com